EUVIMEDEUVIMED entdecken
Vergleichsstudie

Transcatheter Mitral Valve Implantation Compared to Surgery: One-Year Clinical Outcome

Hendrik Ruge iD, Melchior Burri iD, Magdalena Erlebach iD, Stephanie S Voss iD, Nazan Puluca, Caterina Campanella, Felix Wirth, Erion Xhepa, Andreas Stein, Markus Krane

The Thoracic and Cardiovascular Surgeon · 2026-06 · 74 (04) · 316-323

DOI: 10.1055/a-2650-7092 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift The Thoracic and Cardiovascular Surgeon, online erschienen am 18.07.2025. Verfasst von Hendrik Ruge und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Surgery, Institute Insure, German Heart Centre Munich, School of Medicine and Health, Technical University of Munich, Mu…. Hauptthemen laut MEDLINE: Transcatheter Mitral Valve Replacement, Mitral Valve, Mitral Valve Insufficiency, Heart Valve Prosthesis Implantation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Transcatheter mitral valve implantation (TMVI) is an evolving technology, expanding therapeutic options for patients at higher operative risk. Data comparing TMVI to surgical mitral valve replacement (SMVR) are lacking. Clinical outcomes after TMVI with the Tendyne mitral valve and SMVR were compared utilizing propensity score matching, including seven variables. The current study reports 1-year clinical outcomes after TMVI and 1-year mortality in both cohorts. Forty TMVI patients were compared to 80 SMVR patients. Baseline characteristics included in the matching protocol were well balanced: Age (78 years [interquartile range, IQR 75; 80] vs. 78 years [IQR 73; 80], p = 0.797), female sex (60% vs. 60% [p = 1.0]), atrial fibrillation (68% vs. 64% [p = 0.839]), previous coronary artery bypass grafting (CABG) or surgical aortic valve replacement (25% vs. 25% [p = 1.0]), body mass index (kg/m2; 26 ± 4 vs. 25 ± 4 [p = 0.723]), mitral valve pathology (regurgitation 70% vs. 74%, stenosis 7.5% vs. 4%, and mixed disease 22.5% vs. 23% [p = 0.649]), and concomitant tricuspid regurgitation (35% vs. 30% [p = 0.678]). Thirty-day mortality was similar in both groups (TMVI, n = 1, 2.5%; SMVR, n = 3, 3.75%, p = 0.47). Kaplan–Meier estimated survival at 1 year was comparable after TMVI (80 ± 6% [95% CI 69–93%]) and SMVR (86 ± 4% [95% CI 79–94%], p = 0.18) with seven additional deaths beyond 30 days in the TMVI group and eight in the SMVR group. In the TMVI group, two were non-cardiovascular deaths for encephalitis and sepsis after hip replacement, and five were cardiovascular deaths. In the SMVR group, one patient died due to intestinal ischemia, and in seven patients, the cause of death is unknown. At 1 year, in all TMVI patients, echocardiography showed ≤mild paravalvular regurgitation. Within 1 year after TMVI, 21 patients (52.5%) required rehospitalization for heart failure symptoms. TMVI and SMVR in a propensity score-matched cohort displaying an intermediate surgical risk resulted in similar 1-year survival. TMVI achieved a sustained MR elimination at 1 year, and 80% of patients presented in the New York Heart Association (NYHA) class I or II.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Transcatheter Mitral Valve ReplacementMitral ValveMitral Valve InsufficiencyHeart Valve Prosthesis ImplantationMitral Valve StenosisHumansFemaleRisk FactorsAgedTime FactorsMaleAged, 80 and overRisk AssessmentHeart Valve ProsthesisTreatment OutcomeRetrospective StudiesPostoperative ComplicationsRecovery of Function

Autor:innen und Institutionen

  • Department of Cardiovascular Surgery, Institute Insure, German Heart Centre Munich, School of Medicine and Health, Technical University of Munich, Munich, Germany.
  • Department of Cardiology, German Heart Centre Munich, School of Medicine and Health, Technical University of Munich, Munich, Germany.
  • Department of Anaesthesiology, German Heart Centre Munich, School of Medicine and Health, Technical University of Munich, Munich, Germany.
  • German Centre for Cardiovascular Research (DZHK)-Partner Site Munich Heart Alliance, Munich, Germany.

ORCID-Profile: Hendrik Ruge, Melchior Burri, Magdalena Erlebach, Stephanie S Voss

Zitieren

APA

Ruge, H., Burri, M., Erlebach, M., Voss, S. S., Puluca, N., Campanella, C., Wirth, F., Xhepa, E., Stein, A., & Krane, M. (2026). Transcatheter Mitral Valve Implantation Compared to Surgery: One-Year Clinical Outcome. The Thoracic and Cardiovascular Surgeon, 74(04), 316-323. https://doi.org/10.1055/a-2650-7092

Vancouver

Ruge H, Burri M, Erlebach M, Voss SS, Puluca N, Campanella C, et al. Transcatheter Mitral Valve Implantation Compared to Surgery: One-Year Clinical Outcome. The Thoracic and Cardiovascular Surgeon. 2026;74(04):316-323. doi:10.1055/a-2650-7092

BibTeX
@article{Ruge2026,
  author = {Ruge, Hendrik and Burri, Melchior and Erlebach, Magdalena and Voss, Stephanie S and Puluca, Nazan and Campanella, Caterina and Wirth, Felix and Xhepa, Erion and Stein, Andreas and Krane, Markus},
  title = {Transcatheter Mitral Valve Implantation Compared to Surgery: One-Year Clinical Outcome},
  journal = {The Thoracic and Cardiovascular Surgeon},
  year = {2026},
  volume = {74},
  number = {04},
  pages = {316--323},
  doi = {10.1055/a-2650-7092}
}
Kostenlos starten →